FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 23, 2011

Primary Completion Date

December 13, 2012

Study Completion Date

May 26, 2015

Conditions
Pancreatic CancerAdenocarcinomaPancreatic Neoplasms
Interventions
DRUG

FOLFIRINOX, IPI-926

"Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle."

Trial Locations (3)

53792

University of Wisconsin Comprehensive Cancer Center, Madison

60637

University of Chicago Comprehensive Cancer Center, Chicago

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Sponsors
All Listed Sponsors
collaborator

Infinity Pharmaceuticals, Inc.

INDUSTRY

lead

Andrew Ko

OTHER

NCT01383538 - FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter